According to the protocol, the only treatment given was either SIR-Spheres® Y-90 resin microspheres or sorafenib. No further treatment was planned.
However, a total of 107 (23.3%) patients received a second treatment including 15 patients who received it before radiologic progression (11 patients in the SIRT arm and 4 in the sorafenib arm).
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.